TapewireFind a company

person · Reporting owner

TREACE JAMES T

Disclosed activity across 1 company

Tapewire entity
88223
SEC CIK
0001185191

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
TREACE MEDICAL CONCEPTS, INC.TMCI · Entity 5943DirectorAugust 15, 2024August 19, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

TREACE MEDICAL CONCEPTS, INC.

Report date August 15, 2024 · Filed August 19, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect1,223,441 Reported balance After 2024-08-15 transaction · row 1
1 source row

Row 1 · 2024-08-15 · Purchase · Acquired 84,000 · Balance 1,223,441

F1: The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $5.9100 to $6.0450 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.

Common StockSEC Table I · non-derivativeIndirectBy spouse556,183 Reported balance Holding disclosure · report date 2024-08-15 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 556,183

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $5.9100 to $6.0450 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
December 20, 2021 Filed Dec 22, 2021 19:03 UTC TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 OtherCommon Stock 406,183 $0.00 $0.00
Disclosure

SEC source: 0001567619-21-022459 · doc1.xml · nonDerivative · entry 7

TREACE JAMES T · CIK 0001185191 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By spouse

Disclosed balance after: 1,006,183

F6 · kind: Includes pro rata distribution from J&A Group, LLC.

Read SEC document
December 20, 2021 Filed Dec 22, 2021 19:03 UTC TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 OtherCommon Stock 270,789 $0.00 $0.00
Disclosure

SEC source: 0001567619-21-022459 · doc1.xml · nonDerivative · entry 6

TREACE JAMES T · CIK 0001185191 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By J&A Group LLC

Disclosed balance after: 58,883

F5 · kind: Pro rata distribution from J&A Group, LLC to member.

F4 · ownership.nature: James T. Treace and his spouse are managing members of J&A Group, LLC, a Florida limited liability company.

Read SEC document
December 20, 2021 Filed Dec 22, 2021 19:03 UTC TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 OtherCommon Stock 270,789 $0.00 $0.00
Disclosure

SEC source: 0001567619-21-022459 · doc1.xml · nonDerivative · entry 5

TREACE JAMES T · CIK 0001185191 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By J&A Group LLC

Disclosed balance after: 329,672

F5 · kind: Pro rata distribution from J&A Group, LLC to member.

F4 · ownership.nature: James T. Treace and his spouse are managing members of J&A Group, LLC, a Florida limited liability company.

Read SEC document
December 20, 2021 Filed Dec 22, 2021 19:03 UTC TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 OtherCommon Stock 406,183 $0.00 $0.00
Disclosure

SEC source: 0001567619-21-022459 · doc1.xml · nonDerivative · entry 4

TREACE JAMES T · CIK 0001185191 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By J&A Group LLC

Disclosed balance after: 600,461

F5 · kind: Pro rata distribution from J&A Group, LLC to member.

F4 · ownership.nature: James T. Treace and his spouse are managing members of J&A Group, LLC, a Florida limited liability company.

Read SEC document
December 20, 2021 Filed Dec 22, 2021 19:03 UTC TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 OtherCommon Stock 406,183 $0.00 $0.00
Disclosure

SEC source: 0001567619-21-022459 · doc1.xml · nonDerivative · entry 3

TREACE JAMES T · CIK 0001185191 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By J&A Group LLC

Disclosed balance after: 1,006,644

F5 · kind: Pro rata distribution from J&A Group, LLC to member.

F4 · ownership.nature: James T. Treace and his spouse are managing members of J&A Group, LLC, a Florida limited liability company.

Read SEC document
December 20, 2021 Filed Dec 22, 2021 19:03 UTC TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 SaleCommon Stock 400 $16.30 $6,519.52
Disclosure

SEC source: 0001567619-21-022459 · doc1.xml · nonDerivative · entry 2

TREACE JAMES T · CIK 0001185191 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By J&A Group LLC

Disclosed balance after: 1,412,827

F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $16.275 to $16.32 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4 · ownership.nature: James T. Treace and his spouse are managing members of J&A Group, LLC, a Florida limited liability company.

Read SEC document
December 20, 2021 Filed Dec 22, 2021 19:03 UTC TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 SaleCommon Stock 15,719 $15.69 $246,587.10
Disclosure

SEC source: 0001567619-21-022459 · doc1.xml · nonDerivative · entry 1

TREACE JAMES T · CIK 0001185191 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By J&A Group LLC

Disclosed balance after: 1,413,227

F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $15.205 to $16.10 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4 · ownership.nature: James T. Treace and his spouse are managing members of J&A Group, LLC, a Florida limited liability company.

Read SEC document
December 15, 2021 Filed Dec 17, 2021 17:51 UTC TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 SaleCommon Stock 474 $16.86 $7,993.68
Disclosure

SEC source: 0001567619-21-022289 · doc1.xml · nonDerivative · entry 2

TREACE JAMES T · CIK 0001185191 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,055,258

F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $16.69 to $17.02 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
December 15, 2021 Filed Dec 17, 2021 17:51 UTC TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 SaleCommon Stock 74,526 $16.06 $1,196,649.08
Disclosure

SEC source: 0001567619-21-022289 · doc1.xml · nonDerivative · entry 1

TREACE JAMES T · CIK 0001185191 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,055,732

F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $15.63 to $16.61 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
November 24, 2021 Filed Nov 24, 2021 20:49 UTC TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 SaleCommon Stock 17,000 $17.83 $303,036.90
Disclosure

SEC source: 0001567619-21-021185 · doc1.xml · nonDerivative · entry 5

TREACE JAMES T · CIK 0001185191 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · J&A Group, LLC

Disclosed balance after: 1,428,946

F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F6 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $17.12 to $18.0750 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F7 · ownership.nature: James T. Treace and his spouse are managing members of J&A Group, LLC, a Florida limited liability company.

Read SEC document
November 23, 2021 Filed Nov 24, 2021 20:49 UTC TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 SaleCommon Stock 1,736 $18.41 $31,959.76
Disclosure

SEC source: 0001567619-21-021185 · doc1.xml · nonDerivative · entry 4

TREACE JAMES T · CIK 0001185191 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · J&A Group, LLC

Disclosed balance after: 1,445,946

F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F5 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $18.21 to $18.50 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F7 · ownership.nature: James T. Treace and his spouse are managing members of J&A Group, LLC, a Florida limited liability company.

Read SEC document
November 23, 2021 Filed Nov 24, 2021 20:49 UTC TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 SaleCommon Stock 15,264 $17.37 $265,128.05
Disclosure

SEC source: 0001567619-21-021185 · doc1.xml · nonDerivative · entry 3

TREACE JAMES T · CIK 0001185191 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · J&A Group, LLC

Disclosed balance after: 1,447,682

F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F4 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $17.04 to $17.66 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F7 · ownership.nature: James T. Treace and his spouse are managing members of J&A Group, LLC, a Florida limited liability company.

Read SEC document
November 22, 2021 Filed Nov 24, 2021 20:49 UTC TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 SaleCommon Stock 146 $19.39 $2,830.94
Disclosure

SEC source: 0001567619-21-021185 · doc1.xml · nonDerivative · entry 2

TREACE JAMES T · CIK 0001185191 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · J&A Group, LLC

Disclosed balance after: 1,462,946

F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $19.32 to $19.54 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F7 · ownership.nature: James T. Treace and his spouse are managing members of J&A Group, LLC, a Florida limited liability company.

Read SEC document
November 22, 2021 Filed Nov 24, 2021 20:49 UTC TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 SaleCommon Stock 15,854 $18.51 $293,457.54
Disclosure

SEC source: 0001567619-21-021185 · doc1.xml · nonDerivative · entry 1

TREACE JAMES T · CIK 0001185191 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · J&A Group, LLC

Disclosed balance after: 1,463,092

F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $18.13 to $19.09 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F7 · ownership.nature: James T. Treace and his spouse are managing members of J&A Group, LLC, a Florida limited liability company.

Read SEC document
November 17, 2021 Filed Nov 17, 2021 20:32 UTC TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 SaleCommon Stock 25,000 $20.33 $508,250.00
Disclosure

SEC source: 0001567619-21-020693 · doc1.xml · nonDerivative · entry 4

TREACE JAMES T · CIK 0001185191 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,130,258

F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F5 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.87 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
November 16, 2021 Filed Nov 17, 2021 20:32 UTC TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 SaleCommon Stock 25,000 $20.86 $521,500.00
Disclosure

SEC source: 0001567619-21-020693 · doc1.xml · nonDerivative · entry 3

TREACE JAMES T · CIK 0001185191 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,155,258

F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F4 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $20.46 to $21.18 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
November 15, 2021 Filed Nov 17, 2021 20:32 UTC TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 SaleCommon Stock 5,515 $21.41 $118,076.15
Disclosure

SEC source: 0001567619-21-020693 · doc1.xml · nonDerivative · entry 2

TREACE JAMES T · CIK 0001185191 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,180,258

F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $20.99 to $21.87 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
November 15, 2021 Filed Nov 17, 2021 20:32 UTC TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 SaleCommon Stock 19,485 $20.41 $397,688.85
Disclosure

SEC source: 0001567619-21-020693 · doc1.xml · nonDerivative · entry 1

TREACE JAMES T · CIK 0001185191 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,185,773

F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $19.98 to $20.95 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
November 12, 2021 Filed Nov 17, 2021 20:32 UTC TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 GiftCommon Stock 600,000 $0.00 $0.00
Disclosure

SEC source: 0001567619-21-020693 · doc1.xml · nonDerivative · entry 7

TREACE JAMES T · CIK 0001185191 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,130,258

F8 · kind: Gift transfer to reporting person's spouse.

Read SEC document
October 27, 2021 Filed Nov 17, 2021 20:32 UTC TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 GiftCommon Stock 200,000 $0.00 $0.00
Disclosure

SEC source: 0001567619-21-020693 · doc1.xml · nonDerivative · entry 6

TREACE JAMES T · CIK 0001185191 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,730,258

F7 · kind: Gift transfer to a second natural person.

Read SEC document
October 27, 2021 Filed Nov 17, 2021 20:32 UTC TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 GiftCommon Stock 200,000 $0.00 $0.00
Disclosure

SEC source: 0001567619-21-020693 · doc1.xml · nonDerivative · entry 5

TREACE JAMES T · CIK 0001185191 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,930,258

F6 · kind: Gift transfer to a natural person.

Read SEC document
April 27, 2021 Filed Apr 29, 2021 21:09 UTC TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 ConversionSeries A Preferred Stock · Derivative 569,067 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-017461 · doc4.xml · derivative · entry 6

TREACE JAMES T · CIK 0001185191 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · J&A Group, LLC

Disclosed balance after: 0

Underlying: Common Stock · 569,067 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F1 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F1 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F2 · ownership.nature: James T. Treace and his spouse are managing members of J&A Group, LLC, a Florida limited liability company.

Read SEC document
April 27, 2021 Filed Apr 29, 2021 21:09 UTC TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 ConversionSeries A Preferred Stock · Derivative 399,632 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-017461 · doc4.xml · derivative · entry 5

TREACE JAMES T · CIK 0001185191 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 399,633 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F1 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F1 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The shares had no expiration date.

Read SEC document
April 27, 2021 Filed Apr 29, 2021 21:09 UTC TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 OtherSeries A Preferred Stock · Derivative 13,169 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-017461 · doc4.xml · derivative · entry 4

TREACE JAMES T · CIK 0001185191 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · J&A Group, LLC

Disclosed balance after: 569,067

Underlying: Common Stock · 13,169 shares

Expires not disclosed

F1 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F3 · derivative.exercise_price: The Reporting Person received Series A Preferred Stock as a payment-in-kind dividend.

F1 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F3 · derivative.exercise_date: The Reporting Person received Series A Preferred Stock as a payment-in-kind dividend.

F1 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F3 · derivative.expiration_date: The Reporting Person received Series A Preferred Stock as a payment-in-kind dividend.

F2 · ownership.nature: James T. Treace and his spouse are managing members of J&A Group, LLC, a Florida limited liability company.

Read SEC document
April 27, 2021 Filed Apr 29, 2021 21:09 UTC TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 OtherSeries A Preferred Stock · Derivative 9,250 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-017461 · doc4.xml · derivative · entry 3

TREACE JAMES T · CIK 0001185191 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 399,633

Underlying: Common Stock · 9,250 shares

Expires not disclosed

F1 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F3 · derivative.exercise_price: The Reporting Person received Series A Preferred Stock as a payment-in-kind dividend.

F1 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F3 · derivative.exercise_date: The Reporting Person received Series A Preferred Stock as a payment-in-kind dividend.

F1 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F3 · derivative.expiration_date: The Reporting Person received Series A Preferred Stock as a payment-in-kind dividend.

Read SEC document
April 27, 2021 Filed Apr 29, 2021 21:09 UTC TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 ConversionCommon Stock 569,067 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-21-017461 · doc4.xml · nonDerivative · entry 2

TREACE JAMES T · CIK 0001185191 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · J&A Group, LLC

Disclosed balance after: 1,478,946

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F2 · ownership.nature: James T. Treace and his spouse are managing members of J&A Group, LLC, a Florida limited liability company.

Read SEC document
April 27, 2021 Filed Apr 29, 2021 21:09 UTC TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 ConversionCommon Stock 399,633 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-21-017461 · doc4.xml · nonDerivative · entry 1

TREACE JAMES T · CIK 0001185191 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,205,258

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The shares had no expiration date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.